OncoMatch/Clinical Trials/NCT06826118
Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma
Is NCT06826118 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Axicabtagene Ciloleucel for lymphoma.
Treatment: Axicabtagene Ciloleucel — A prospective collection of data on the treatment of Chinese patients with relapsed/refractory follicular lymphoma (FL) using Axicabtagene Ciloleucel Injection, and evaluation of the efficacy and safety of Axicabtagene Ciloleucel Injection in this treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-CD20 monoclonal antibody in combination with an alkylating agent
Prior therapy must include: anti-CD20 monoclonal antibody in combination with an alkylating agent (anti-CD20 monoclonal antibody monotherapy is not eligible as a line of therapy for eligibility)
Cannot have received: CD19-targeted therapy
Previous CD19-targeted therapy
Cannot have received: chimeric antigen receptor cell therapy or other genetically modified T-cell therapy
Previous chimeric antigen receptor cell therapy or other genetically modified T-cell therapy
Cannot have received: autologous hematopoietic stem cell transplantation
Autologous Hematopoietic Stem Cell Transplantation Within 6 Weeks Prior to Scheduled Infusion
Cannot have received: allogeneic hematopoietic stem cell transplantation
Has performed allogeneic hematopoietic stem cell transplants
Lab requirements
Blood counts
ANC ≥ 1.0×10^9/L; Platelet count ≥ 75×10^9/L; Absolute lymphocyte count ≥ 0.1×10^9/L
Kidney function
serum creatinine ≤ 1.5 x ULN or creatinine clearance (CCr) ≥ 60 mL/min (Cockcroft-Gault)
Liver function
total bilirubin (TBIL) ≤ 1.5 x ULN (except Gilbert's syndrome); ALT and AST ≤ 2.5 x ULN
Cardiac function
ejection fraction ≥ 50%, absence of pericardial effusion (ECHO), absence of clinically significant cardiac arrhythmia
Adequate renal, hepatic, pulmonary, and cardiac function, defined as: 1) total bilirubin (TBIL) ≤ 1.5 x ULN (except Gilbert's syndrome); 2) ALT and AST ≤ 2.5 x ULN; 3) serum creatinine ≤ 1.5 x ULN or creatinine clearance (CCr) ≥ 60 mL/min (Cockcroft-Gault); 4) cardiac ejection fraction ≥ 50%, absence of pericardial effusion (ECHO), and absence of clinically significant cardiac arrhythmia; 5) baseline transcutaneous oxygen saturation > 92% under room ventilation; 6) absence of clinically significant chest pain; and 7) absence of clinically significant pleural effusion.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify